SPOTLIGHT: Glaxo wraps up Reliant buy

GlaxoSmithKline says it's completed its $1.65 billion buyout of U.S.-based heart drug specialist Reliant Pharmaceuticals; the Federal Trade Commission ended the mandatory antitrust waiting period early. Release